Beleggen.nl Markt MonitorMarkt Monitor

Innoconcepts Terug naar discussie overzicht

Handel in Proventec opgeschort

91 Posts
Pagina: «« 1 2 3 4 5 | Laatste | Omlaag ↓
  1. pardon 9 september 2010 18:53
    "Proventec" or the "Company")



    Proposed Scheme of Arrangement

    and further Update re Suspension



    Further to the Company's announcement on 8 July 2010, the Board of Proventec plc (AIM:PROV, Alternext:ALPTC) is pleased to announce that, after detailed discussions with applicable parties, it has come to an agreement in principle with the representatives of the holders of more than 75% in value (the "Principal Loan Noteholders") of the £15 million 8.5% fixed rate convertible guaranteed unsecured loan notes 2012 (the "Loan Notes"), as to the terms and means by which the Company intends to restructure the Loan Notes (and the Company's other loan debts of circa £6 million, the benefit of which are proposed to be transferred to the holders of the Loan Notes (the "Loan Noteholders") by InnoConcepts N.V.) (such proposed restructuring, the "Transaction").



    It is intended that the Transaction will be effected by way of a scheme of arrangement, pursuant to Part 26 of the Companies Act 2006, between the Loan Noteholders and the Company and will be subject, inter alia, to the approval of the board of Proventec and of the applicable majorities of the Loan Noteholders and of the shareholders of Proventec and to the sanctioning of the scheme of arrangement by the Companies Court (part of the Chancery Division of the High Court). The Transaction would result in a significant reduction of the Company's term debt to a principal sum of £7 million (by way of a conversion of the loan debts referred to above, and of a significant proportion of the Loan Notes, into equity at a rate of 57p per new ordinary share) and would result in the current holders of the Loan Notes holding an additional 61.23 per cent of the enlarged issued share capital of the Company.



    As part of the agreement in principle reached with the Principal Loan Noteholders to effect the Transaction, £1.5 million out of the new £2.5 million cash injection (referred to in the announcement made by the Company on 8 July 2010) has been authorised for release to the Company by the Principal Loan Noteholders. Given the anticipated timetable for completion of the Transaction, the Principal Loan Noteholders have made this £1.5 million available in the interim, to support the Company's trading and growth plans. The balance of these new funds, being £1 million, would be available to be drawn down by the Company after the scheme of arrangement has become effective.



    Proventec intends to send circulars to the Loan Noteholders and to its shareholders explaining the background to and reasons for the proposals, the effect of the Transaction and how it will benefit the Company. The circular to shareholders will convene a general meeting of Proventec's shareholders (and the circular to the Loan Noteholders will convene applicable meeting(s) of the Loan Noteholders) to approve the Transaction. Extraordinary resolutions have been passed (on 6 July 2010 and 3 September 2010) by the Principal Loan Noteholders in anticipation of, and in order to facilitate, the Transaction (and to facilitate the release of the guarantee given by InnoConcepts N.V. in respect of the repayment of the Loan Notes). Copies of these resolutions will be made available in the Investors' section of the Company's website, www.proventecplc.com
  2. pardon 9 september 2010 19:00
    Dus nu word een heel groot gedeelte van de oblies omgezet in aandelen,er komen dus 61% aandelen bij tegen een prijs van 57 pence op zich niet verkeerd denk ik.
    De koers staat nu op 0,54 eurocent
  3. pardon 10 september 2010 09:27
    Nee dit heeft niets meer met inno te maken,zij zijn het geweest die met een flinke smak geld Proventec op de been houden.
  4. Hugo44 10 september 2010 11:26
    Af en toe koopt iemand alles tot 20 cent, maar ik denk niet dat de koers snel hoger zal gaan.
  5. Beate 10 september 2010 20:51
    quote:

    schreef:

    Beate

    Bedoel je mogelijk of onmogeljk ??

    Herman
    Ik bedoel: onmogelijk. Je ziet vaak bij Inno dat het onmogelijke toch gebeurt. Vrouwenlogica, misschien?

    Groetjes,
    Beate

91 Posts
Pagina: «« 1 2 3 4 5 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.007
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.426
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.564
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.692
Aedifica 3 902
Aegon 3.258 322.682
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.048
Ahold 3.538 74.328
Air France - KLM 1.025 35.011
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.575
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.847
AMG 971 133.179
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 487
Antonov 22.632 153.605
Aperam 92 14.965
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.750
Arcelor Mittal 2.033 320.633
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.726
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.087
ASML 1.766 106.316
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 484
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392